This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study (XV CHINA SAS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Abbott Vascular
ClinicalTrials.gov Identifier:
NCT01249027
First received: November 24, 2010
Last updated: October 11, 2015
Last verified: October 2015
November 24, 2010
October 11, 2015
November 2010
January 2017   (Final data collection date for primary outcome measure)
  • (This study has no primary endpoint, all endpoints are of equal weight). Incidence of the composite rate of cardiac death and any myocardial infarction (MI) (including Q-wave and non-Q-wave) [ Time Frame: 1 year ]
  • (This study has no primary endpoint, all endpoints are of equal weight). Incidence of the composite rate of cardiac death and any myocardial infarction (MI) (including Q-wave and non-Q-wave) [ Time Frame: 2 years ]
  • (This study has no primary endpoint, all endpoints are of equal weight). Incidence of the composite rate of cardiac death and any myocardial infarction (MI) (including Q-wave and non-Q-wave) [ Time Frame: 3 years ]
  • (This study has no primary endpoint, all endpoints are of equal weight). Incidence of the composite rate of cardiac death and any myocardial infarction (MI) (including Q-wave and non-Q-wave) [ Time Frame: 4 years ]
  • (This study has no primary endpoint, all endpoints are of equal weight). Incidence of the composite rate of cardiac death and any myocardial infarction (MI) (including Q-wave and non-Q-wave) [ Time Frame: 5 years ]
Same as current
Complete list of historical versions of study NCT01249027 on ClinicalTrials.gov Archive Site
  • Stent thrombosis (definite and probable) [ Time Frame: 1 year ]
  • Stent thrombosis (definite and probable) [ Time Frame: 2 years ]
  • Stent thrombosis (definite and probable) [ Time Frame: 3 years ]
  • Stent thrombosis (definite and probable) [ Time Frame: 4 years ]
  • Stent thrombosis (definite and probable) [ Time Frame: 5 years ]
  • Incidence of the composite rate of all death, any MI, and any repeat revascularization [ Time Frame: 1 year ]
  • Incidence of the composite rate of all death, any MI, and any repeat revascularization [ Time Frame: 2 years ]
  • Incidence of the composite rate of all death, any MI, and any repeat revascularization [ Time Frame: 3 years ]
  • Incidence of the composite rate of all death, any MI, and any repeat revascularization [ Time Frame: 4 years ]
  • Incidence of the composite rate of all death, any MI, and any repeat revascularization [ Time Frame: 5 years ]
  • Incidence of the composite rate of cardiac death, MI attributed to the target vessel (TV-MI), and target lesion revascularization (TLR) [ Time Frame: 1 year ]
  • Incidence of the composite rate of cardiac death, MI attributed to the target vessel (TV-MI), and target lesion revascularization (TLR) [ Time Frame: 2 years ]
  • Incidence of the composite rate of cardiac death, MI attributed to the target vessel (TV-MI), and target lesion revascularization (TLR) [ Time Frame: 3 years ]
  • Incidence of the composite rate of cardiac death, MI attributed to the target vessel (TV-MI), and target lesion revascularization (TLR) [ Time Frame: 4 years ]
  • Incidence of the composite rate of cardiac death, MI attributed to the target vessel (TV-MI), and target lesion revascularization (TLR) [ Time Frame: 5 years ]
  • Incidence of the composite rate of cardiac death, TV-MI and ischemia-driven TLR [ Time Frame: 1 year ]
  • Incidence of the composite rate of cardiac death, TV-MI and ischemia-driven TLR [ Time Frame: 2 years ]
  • Incidence of the composite rate of cardiac death, TV-MI and ischemia-driven TLR [ Time Frame: 3 years ]
  • Incidence of the composite rate of cardiac death, TV-MI and ischemia-driven TLR [ Time Frame: 4 years ]
  • Incidence of the composite rate of cardiac death, TV-MI and ischemia-driven TLR [ Time Frame: 5 years ]
  • Incidence of the composite rate of cardiac death, all MI and target vessel revascularization (TVR) [ Time Frame: 1 year ]
  • Incidence of the composite rate of cardiac death, all MI and target vessel revascularization (TVR) [ Time Frame: 2 years ]
  • Incidence of the composite rate of cardiac death, all MI and target vessel revascularization (TVR) [ Time Frame: 3 years ]
  • Incidence of the composite rate of all death and any MI [ Time Frame: 1 year ]
  • Incidence of the composite rate of all death and any MI [ Time Frame: 2 years ]
  • Incidence of the composite rate of all death and any MI [ Time Frame: 3 years ]
  • Incidence of the composite rate of all death and any MI [ Time Frame: 4 years ]
  • Incidence of the composite rate of all death and any MI [ Time Frame: 5 years ]
  • Death [ Time Frame: 1 year ]
  • Death [ Time Frame: 2 years ]
  • Death [ Time Frame: 3 years ]
  • Death [ Time Frame: 4 years ]
  • Death [ Time Frame: 5 years ]
  • Any MI [ Time Frame: 1 year ]
  • Any MI [ Time Frame: 2 years ]
  • Any MI [ Time Frame: 3 years ]
  • Any MI [ Time Frame: 4 years ]
  • Any MI [ Time Frame: 5 years ]
  • Revascularization (target lesion, target vessel, and nontarget vessel) [ Time Frame: 1 year ]
  • Revascularization (target lesion, target vessel, and nontarget vessel) [ Time Frame: 2 years ]
  • Revascularization (target lesion, target vessel, and nontarget vessel) [ Time Frame: 3 years ]
  • Revascularization (target lesion, target vessel, and nontarget vessel) [ Time Frame: 4 years ]
  • Revascularization (target lesion, target vessel, and nontarget vessel) [ Time Frame: 5 years ]
  • Major bleeding complications [ Time Frame: 1 year ]
  • Major bleeding complications [ Time Frame: 2 years ]
  • Major bleeding complications [ Time Frame: 3 years ]
  • Major bleeding complications [ Time Frame: 4 years ]
  • Major bleeding complications [ Time Frame: 5 years ]
  • Incidence of the composite rate of cardiac death, all MI and target vessel revascularization (TVR) [ Time Frame: 4 years ]
  • Incidence of the composite rate of cardiac death, all MI and target vessel revascularization (TVR) [ Time Frame: 5 years ]
  • Patient compliance with DAPT [ Time Frame: 1 year ]
    Dual Anti-platelet Therapy (DAPT)
  • Patient compliance with DAPT [ Time Frame: 2 years ]
    Dual Anti-platelet Therapy (DAPT)
  • Patient compliance with DAPT [ Time Frame: 3 years ]
    Dual Anti-platelet Therapy (DAPT)
  • Patient compliance with DAPT [ Time Frame: 4 years ]
    Dual Anti-platelet Therapy (DAPT)
  • Patient compliance with DAPT [ Time Frame: 5 years ]
    Dual Anti-platelet Therapy (DAPT)
Same as current
Not Provided
Not Provided
 
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to:

  • Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use
  • Evaluate patient compliance to dual antiplatelet therapy (DAPT)
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
General Chinese interventional cardiology population
  • Angioplasty
  • Chronic Coronary Occlusion
  • Stent Thrombosis
  • Vascular Disease
  • Myocardial Ischemia
  • Coronary Artery Stenosis
  • Coronary Disease
  • Coronary Artery Disease
  • Coronary Restenosis
Device: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
Observational
Single arm prospective, observational, single-arm, open-label, multicenter, postapproval registry study using XIENCE V® Everolimus Eluting Coronary Stent System (EECSS).
Intervention: Device: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
2605
January 2017
January 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient or patient's legally-authorized representative agrees to participate in this study by signing the Ethics Committee-approved informed consent form (ICF).
  • Only XIENCE V stent(s) is/are implanted into the coronary vasculature during the index procedure.

Exclusion Criteria:

  • The inability to obtain a signed ICF
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01249027
10-388
No
Not Provided
Not Provided
Not Provided
Abbott Vascular
Abbott Vascular
Not Provided
Principal Investigator: Junbo Ge, MB, MSc, MD, FACC, FESC, FSCAI Fudan University
Principal Investigator: Jiyan Chen, MD Institute of Cardiovascular Guangdong, Guangdong Provincial People's Hospital
Principal Investigator: YuJie Zhou, MD, Ph.D An Zhen Hospital
Abbott Vascular
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP